Abstract
Attempts were made to administer chemotherapy (CT) and/or radiotherapy (RT) combined with hyperthermia (HT) to treat advanced lung cancer, although HT has rarely been used in lung cancer treatments.
This report examines the survival rate in 30 non-small-cell lung cancer (NSCLC) patients who were treated with CT combined with HT beginning with initial therapeutic efforts. The average patient age was 65.1 years old. There were 28 male patients, and 2 female patients. Twenty one patients were classified as having adenocarcinomas, and 9 patients were classified as having squamous cell carcinomas. Stage classification indicated 1 patient was stage IIB, 3 patients were stage IIIA, 11 patients were stage IIIB, and 15 patients were stage IV. The performance status of all patients was good (0-2). Systemic chemotherapy we used were paclitaxel plus carboplatin, camptothecine plus cisplatin (CDDP), mitomycin-C plus vinorelbin plus CDDP, gemcitabin plus CDDP, and TS-1 alone. All patients were administered this therapy safely.
The survival rate for 1-year survival of this therapy was 89.0%, the rate for 2-year survival was 64.5%, and the rate for 3-year survival was 32.5%. The median survival time was 27 months.
It was concluded that this combined therapy can improve the prognosis for NSCLC, and that this therapy can be recommended for additional patients.
